Lowdell Mark William
Known title: Chief Scientific OfficerCIK: 0001767037
Associated companies
Transaction History
| INMB | ▲ Buy | Option Exercise | 7,211 | $10K | 7/2/2026 | View on chart |
| INMB | ▲ Buy | Grant | 14,423 | $120K | 4/19/2024 | View on chart |
| INMB | ▲ Buy | Grant | 23,590 | $199K | 3/22/2022 | View on chart |
| INMB | ▼ Sell | Open Market | 701 | $14K | 11/3/2021 | View on chart |
| INMB | ▼ Sell | Open Market | 2,357 | $47K | 10/27/2021 | View on chart |
| INMB | ▼ Sell | Open Market | 400 | $8K | 10/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
INmune Bio Announces Attendance at 2026 Maxim Growth Summit
INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.
INmune Bio Announces Attendance at 2026 Maxim Growth Summit. INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.